PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

Core Insights - PacBio has appointed Haorui Gene as an official distributor in China to enhance access to its HiFi long-read sequencing technology, particularly in transfusion medicine and hematology [1][3][5] - Haorui Gene has established itself as a significant player in blood typing genomics since its founding in 2020, deploying multiple sequencing systems to improve HLA typing and blood group genotyping [2][5] - The partnership aims to make PacBio's HiFi sequencing the preferred method in blood genomics, emphasizing its accuracy in critical areas for transfusion safety and donor matching [3][5][6] Company Overview - PacBio is a leading life science technology company focused on high-quality sequencing solutions, including HiFi long-read and SBB short-read sequencing technologies [7] - Haorui Gene is recognized for its innovative contributions to clinical long-read sequencing and precision medicine through advanced genomic technologies [9] Partnership Details - Under the agreement, Haorui Gene will distribute PacBio's Vega platform across China, providing comprehensive support for clinical laboratories and blood centers [4][5] - The collaboration is positioned to address the growing demand for high-precision sequencing in clinical genomics, particularly in hematology [6]